RMC No. 25-2025 confirms FDA updates to VAT-exempt medicines for diabetes, hypertension, high cholesterol, and mental illness under TRAIN and CREATE.
Businesses selling, purchasing, distributing, or accounting for medicines covered by the FDA’s updated VAT-exempt list must immediately review their product master files, invoicing settings, and VAT treatment because the VAT exemption takes effect upon the FDA’s publication of the updated list. RMC No. 25-2025 matters now because it confirms that certain medicines for diabetes, hypertension, high cholesterol, and mental illness are to be included in the published list of VAT-exempt products under the TRAIN Law and the CREATE Act.
What RMC No. 25-2025 Changed
RMC No. 25-2025 publishes the full text of the February 24, 2025 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt products under Republic Act No. 10963, or the TRAIN Law, and Republic Act No. 11534, or the CREATE Act. The key change is the recognition of FDA-endorsed updates to the list of VAT-exempt medicines, particularly for the inclusion of certain medicines for diabetes, hypertension, high cholesterol, and mental illness.
For Philippine businesses, this is not merely a technical publication. A medicine’s inclusion in the FDA-published VAT-exempt list affects how it should be treated for VAT purposes. Pharmacies, distributors, importers, hospitals, clinics, corporate purchasers, and accounting teams should not wait for year-end reconciliation before checking whether their medicines are covered. Once the product is covered by the FDA update, the sales, purchases, invoicing, and accounting treatment may need to be adjusted to reflect VAT-exempt treatment.
Why the FDA List Matters for VAT Exemption
RMC No. 25-2025 reiterates an important timing rule from Q&A No. 1 of RMC No. 99-2021: the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the list. This means that taxpayers should look to the FDA publication of the updated list when determining the effectivity of the VAT exemption for the covered items.
This timing rule is important for VAT audits, purchase reviews, and customer billing disputes. A taxpayer that treats a product as VAT-exempt too early may face questions on the basis for the exemption. On the other hand, a taxpayer that continues to impose VAT after the product has been properly included in the FDA-published update may create refund, credit memo, customer complaint, or accounting reconciliation issues. The practical compliance point is that the FDA-published list must be matched with the company’s product list and invoice setup.
Who Is Most Affected by RMC No. 25-2025
The most directly affected businesses are those engaged in the sale, purchase, importation, distribution, or reimbursement of medicines for diabetes, hypertension, high cholesterol, and mental illness. This includes pharmacies, drugstores, pharmaceutical distributors, importers, hospitals, clinics, health maintenance organizations, corporate health benefit administrators, and companies with internal medical procurement or employee medicine programs.
CFOs and tax managers of pharmaceutical and healthcare companies should pay close attention because VAT treatment usually flows through multiple business systems: product classification, point-of-sale settings, enterprise resource planning systems, invoice templates, tax codes, customer pricing, supplier billing, and VAT return preparation. A single product classification error can lead to repeated incorrect invoices across many transactions.
Corporate accountants should also review purchases of covered medicines because input VAT treatment and expense recording may be affected. In-house counsel should coordinate with finance and compliance teams where contracts, supply agreements, or purchase orders refer to VAT-inclusive or VAT-exclusive pricing. For government-regulated or institutional purchasers, the documentation trail showing why a product was treated as VAT-exempt should be preserved.
Key Compliance Requirement and Effective Date
The core compliance requirement under RMC No. 25-2025 is to be guided by the FDA-endorsed updates to the list of VAT-exempt products. The RMC is dated April 4, 2025. The FDA letter referenced in the issuance is dated February 24, 2025. However, the operative timing rule emphasized in the circular is that the VAT exemption for covered medicines and medical devices under the CREATE Act becomes effective on the publication by the FDA of the updates to the list.
For businesses, the immediate question should be: are the specific medicines being sold, purchased, imported, distributed, or reimbursed included in the FDA-published updated list? RMC No. 25-2025 does not give a general blanket exemption to every medicine used for diabetes, hypertension, high cholesterol, or mental illness. The safer compliance position is to verify the exact product against the FDA-published VAT-exempt list before changing the VAT treatment.
Common search phrases for this issue include VAT-exempt medicines Philippines 2025, FDA VAT-exempt list CREATE Act, RMC 25-2025 VAT exemption medicines, diabetes hypertension cholesterol mental illness VAT exemption, and BIR VAT-exempt medicines TRAIN CREATE. These phrases matter because tax teams often search by both the BIR issuance number and the practical product category affected.
Penalties and Audit Risk for Non-Compliance
RMC No. 25-2025 does not state a new penalty provision. However, incorrect VAT treatment can still create ordinary tax compliance risk under existing VAT, invoicing, bookkeeping, and tax return rules. The likely exposure is not because RMC No. 25-2025 creates a new penalty, but because a taxpayer may misclassify sales or purchases, issue incorrect invoices, report incorrect VAT amounts, or fail to maintain support for VAT-exempt treatment.
For sellers, the main audit risk is applying VAT-exempt treatment to products that are not actually covered by the FDA-published list, or failing to properly document why VAT was not imposed. For purchasers, the issue may arise when purchase invoices are reviewed for input VAT claims, expense recording, or reimbursement controls. For distributors and pharmacies, repeated product-level errors may multiply across many transactions and branches.
Practical Steps Businesses Should Take Now
First, tax and accounting teams should obtain and review the FDA-published updated list of VAT-exempt products and match it against the company’s active product list. The review should be done at the product level, not merely by broad therapeutic category, because the RMC refers to covered medicines and updates to a list.
Second, businesses should update their invoicing, point-of-sale, and accounting systems only after confirming that the specific medicine is included in the FDA-published update. The effective date should be tied to the FDA publication of the updated list, consistent with the rule reiterated from RMC No. 99-2021.
Third, companies should preserve documentary support showing the basis for VAT-exempt treatment. This should include the relevant FDA-published list, internal product matching records, screenshots or system logs showing when the tax code was changed, and accounting approvals for the change in VAT treatment.
Fourth, contracts, purchase orders, and price lists involving covered medicines should be reviewed. Where pricing is expressed as VAT-inclusive or VAT-exclusive, the parties may need to clarify how VAT-exempt treatment affects the amount payable, rebates, credit memos, or future billing.
Fifth, businesses should train sales, billing, and customer-facing teams. VAT-exempt medicine issues often result in customer questions, especially where a medicine previously carried VAT and later becomes VAT-exempt after inclusion in an updated list. Staff should know that the exemption depends on the FDA-published list and the applicable effective date.
How Ablola, Saribong & Gueco Can Help
RMC No. 25-2025 is a reminder that VAT compliance for medicines is not only a tax return issue. It affects product classification, invoice issuance, customer pricing, supplier billing, accounting controls, and audit defense. Businesses dealing with medicines for diabetes, hypertension, high cholesterol, and mental illness should review their VAT treatment immediately and document the basis for any exemption applied.
Ablola, Saribong & Gueco assists businesses, CFOs, accountants, healthcare companies, distributors, importers, pharmacies, and corporate legal teams in reviewing BIR issuances, implementing VAT compliance procedures, preparing audit-ready documentation, and coordinating tax positions with commercial contracts. For assistance with RMC No. 25-2025, VAT-exempt medicine classification, or BIR compliance planning, visit MakatiLawFirm.com.